|Table of Contents|

Inhibitory effect and mechanism of Brivanib on HepG2 cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 03
Page:
355-357
Research Field:
Publishing date:

Info

Title:
Inhibitory effect and mechanism of Brivanib on HepG2 cells
Author(s):
Han Xinghua1; Wang Zhanggui2
1.Department of Oncology，The Affiliated Provincial Hospital of Anhui Medical University，Anhui Hefei 230001，China；2.Department of Radiation Oncology，The Second People's Hospital of Anhui Province，Anhui Hefei 230001，China.
Keywords:
hepatocellular carcinoma cells; Brivanib; apoptosis; autophagy
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2017.03.005
Abstract:
Objective：To explore the inhibitory effect and mechanism of Brivanib on human hepatocellular carcinoma HepG2 cells.Methods：The anti-proliferative effect of Brivanib on HepG2 cells were assessed by MTS.HepG2 cell apoptosis rate was determined by flow cytometry (FCM) analysis after various concentration Brivanib treatment.The expressions of Bcl-2 and Bax were detected by Western blot.The expression of LC3 were examined by immunofluorescence and Western blot.Results：The anti-proliferative rates were increased in dose-dependant and time-dependant manners.After incubated with different doses of Brivanib，the inhibitory rates of HepG2 cells were (13.06±4.06)%，(20.89±1.83)% and (44.29±2.56)%，respectively.The apoptosis rates were (13.06±4.06)%，(20.89±1.83)% and (44.29±2.56)%,respectively.Which were correlated with the decreasing of Bax and increasing of Bcl-2.Furthermore，the expression of LC3 was increased by 2.5μmol/L Brivanib treatment，and p62 decreased.Conclusion：Brivanib inhibits the proliferation of HepG2 cells，induces apoptosis and activates autophagy.

References:

［1］McGlynn KA，Petrick JL，London WT，et al.Global epidemiology of hepatocellular carcinoma：an emphasis on demographic and regional variability［J］.Clin Liver Dis，2015，19：223-238.
［2］Itokawa N，Atsukawa M，Tsubota A，et al.Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma：a pilot study［J］.Int J Clin Oncol，2016，21：676-683.
［3］Bolos D，Finn RS.Systemic therapy in HCC：lessons from Brivanib［J］.J Hepatol，2014，61：947-950.
［4］Jonker DJ，Rosen LS，Sawyer MB，et al.A phase I study to determine the safety，pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor，Brivanib，in patients with advanced or metastatic solid tumors［J］.Ann Oncol，2011，22：1413-1419.
［5］Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66：115-132.
［6］Qi X，Jia J，Fan D，et al.Brivanib for hepatocellular carcinoma trials：selection bias from barcelona clinic liver cancer stage［J］? J Clin Oncol，2014，32：968-972.
［7］Lee YJ，Jang BK.The role of autophagy in hepatocellular carcinoma［J］.Int J Mol Sci，2015，16：26629-26643.
［8］Wang Z，Han W，Sui X，et al.Autophagy：A novel therapeutic target for hepatocarcinoma［J］.Oncol Lett，2014，7：1345-1351.

Memo

Memo:
安徽省科技攻关项目(编号：1401042007)
Last Update: 2016-12-29